SLC5A2 and diabetes mellitus: Randomized clinically controlled trials (RCTs) and meta-analyses of the results of trials in patients with HF have shown that SGLT2 inhibitors improve cardiovascular outcomes in patients with chronic HF, irrespective of their diabetes status (6).